Advertisement
AXON vs BBIO
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. BridgeBio Pharma (BBIO) Stock Comparison
Key Takeaways
- AXON boasts year-to-date (YTD) gains of 29.11%, significantly outpacing BBIO's 2.58% YTD rise, highlighting stronger momentum in recent market activity.
- AXON, with a market capitalization of $32.4 billion, trades profitably on a price-to-earnings (PE) ratio of 263, while BBIO remains unprofitable amid biotech development costs.
- Recent weeks have seen AXON pull back approximately 25% due to profit-taking and debt concerns, contrasting BBIO's steadier advance near its 52-week high on pipeline progress.
- Analysts rate both stocks positively, with AXON's average target implying substantial upside from current levels around $403, and BBIO targeting around $101 from $75.
- AXON benefits from recurring public safety software revenue, while BBIO hinges on clinical catalysts in genetic diseases.
Introduction
This AXON vs. BBIO stock comparison examines two innovative growth names from distinct sectors: public safety technology and biotechnology. AXON Enterprise delivers hardware and AI-enhanced software to law enforcement, while BridgeBio Pharma advances therapies for genetic disorders. Traders seeking relative performance insights, momentum shifts, and sector contrasts will find value here, especially amid recent market volatility and upcoming catalysts like earnings reports. This analysis draws on verifiable data to illuminate current positioning without speculation.
AXON Overview and Recent Performance
Axon Enterprise, Inc. (AXON) specializes in public safety solutions, including TASER devices, body cameras, and cloud-based software like Axon Evidence and AI tools such as Draft One. The company reported robust Q4 2025 revenue of $797 million, up significantly year-over-year, driven by recurring software and services growth. In recent market activity, AXON shares, trading around $403 after a 1.4% daily gain, have shown volatility. YTD performance stands at 29%, but the stock has retreated about 55% from its 52-week high of $886 amid profit-taking post-earnings and investor concerns over debt levels. Sentiment remains positive, bolstered by AI integrations in public safety and an upcoming Q1 2026 earnings release on May 6, with analysts forecasting continued expansion.
BBIO Overview and Recent Performance
BridgeBio Pharma, Inc. (BBIO) focuses on precision medicines for genetic diseases, with commercial products like Attruby for transthyretin amyloidosis (ATTR-CM) and a pipeline including Phase 3 assets for muscular dystrophy and hypoparathyroidism. Q4 2025 revenue reached $154 million, reflecting Attruby's market traction, though net losses persist at $182 million due to R&D investments. Shares closed at $74.52, up 1.7% daily and near the 52-week high of $85, with YTD gains of 2.6% amid steady sentiment. Recent developments, including positive Phase 3 data for BBP-418 and analyst reiterations of Buy ratings, have supported performance, countering biotech sector pressures. Investors eye pipeline catalysts for potential upside.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the top 25 AI trading bots selected from over 351 total bots, curated for optimal fit in current market conditions. These bots employ diverse strategies—ranging from signal agents to virtual and brokerage agents—across various timeframes, trading styles, and thousands of tickers. Performance metrics vary, emphasizing those with strong historical win rates, returns, and risk-adjusted profiles suited to volatile environments. Whether short-term scalping or longer-term trend following, the selection highlights bots adapting to recent equity rotations and sector shifts. Traders can explore these high-conviction options to enhance strategies amid AXON vs. BBIO dynamics.
Head-to-Head Comparison
AXON and BBIO diverge sharply in business models: AXON's hardware-software ecosystem generates predictable recurring revenue (over 80% from subscriptions), contrasting BBIO's pipeline-dependent biotech model reliant on clinical milestones. Growth drivers include AXON's AI public safety adoption versus BBIO's drug approvals. Recent momentum favors BBIO's stability near highs, while AXON offers higher YTD returns but elevated valuation risks (PE 263) and debt exposure. AXON in industrials/tech shows lower biotech-like volatility, yet both face sector headwinds—regulatory for BBIO, economic sensitivity for AXON. Market sentiment tilts bullish for both, with stronger analyst conviction on AXON's trajectory.
Tickeron AI Verdict
Tickeron's AI models would likely favor AXON in the current environment, given its profitability, superior YTD relative performance, and consistent revenue trends outweighing recent pullbacks. BBIO's pipeline catalysts offer upside potential but introduce higher clinical and binary risks compared to AXON's established growth positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a StrongBuy and BBIO is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileBBIO’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- BBIO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while BBIO’s TA Score has 3 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 6 bearish.
- BBIO’s TA Score: 3 bullish, 3 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -7.49% price change this week, while BBIO (@Biotechnology) price change was +1.32% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -3.31%. For the same industry, the average monthly price growth was -4.26%, and the average quarterly price growth was +13.96%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.11%. For the same industry, the average monthly price growth was +3.26%, and the average quarterly price growth was +1969.89%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
BBIO is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Aerospace & Defense (-3.31% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+7.11% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | BBIO | AXON / BBIO | |
| Capitalization | 33B | 13.5B | 244% |
| EBITDA | 320M | -535.2M | -60% |
| Gain YTD | -27.803 | -9.923 | 280% |
| P/E Ratio | 165.33 | N/A | - |
| Revenue | 2.98B | 580M | 514% |
| Total Cash | 737M | 940M | 78% |
| Total Debt | 1.83B | 2.49B | 73% |
AXON | BBIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 68 | 85 | |
SMR RATING 1..100 | 81 | 100 | |
PRICE GROWTH RATING 1..100 | 63 | 51 | |
P/E GROWTH RATING 1..100 | 63 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 12 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BBIO's Valuation (3) in the null industry is significantly better than the same rating for AXON (75) in the Biotechnology industry. This means that BBIO’s stock grew significantly faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (68) in the Biotechnology industry is in the same range as BBIO (85) in the null industry. This means that AXON’s stock grew similarly to BBIO’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as BBIO (100) in the null industry. This means that AXON’s stock grew similarly to BBIO’s over the last 12 months.
BBIO's Price Growth Rating (51) in the null industry is in the same range as AXON (63) in the Biotechnology industry. This means that BBIO’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (63) in the Biotechnology industry is somewhat better than the same rating for BBIO (100) in the null industry. This means that AXON’s stock grew somewhat faster than BBIO’s over the last 12 months.
| AXON | BBIO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 63% | N/A |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 71% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 67% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 72% | 2 days ago 85% |
| Advances ODDS (%) | 22 days ago 74% | 19 days ago 80% |
| Declines ODDS (%) | 12 days ago 69% | 22 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 69% | N/A |
| Aroon ODDS (%) | 2 days ago 72% | 2 days ago 83% |
Advertisement
BBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with AXON. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To BBIO | 1D Price Change % | ||
|---|---|---|---|---|
| BBIO | 100% | +3.97% | ||
| AXON - BBIO | 44% Loosely correlated | -3.16% | ||
| ARRY - BBIO | 43% Loosely correlated | +6.75% | ||
| PMN - BBIO | 43% Loosely correlated | +1.28% | ||
| KURA - BBIO | 41% Loosely correlated | +4.33% | ||
| DYN - BBIO | 39% Loosely correlated | +5.51% | ||
More | ||||